Precision Oncology: How Understanding Cancer Biology Can Shape Treatment

Cancer is not just a disease—it is a complex biological system of signals, pathways, and genetic changes.

Cancer cells can receive growth signals, respond to molecular instructions, adapt to treatment, and develop mechanisms that help them survive.

This understanding is driving an important shift in modern oncology: precision oncology.

Instead of relying on the same treatment approach for every patient with the same type of cancer, precision oncology focuses on understanding the biological characteristics of an individual’s disease and identifying treatment options that may target specific molecular features.

What Is Precision Oncology?

Precision oncology is an approach to cancer care that uses information about a tumor’s genetic, molecular, and biological characteristics to help guide treatment decisions.

Different cancers—and even different tumors within the same cancer type—can be driven by different molecular pathways.

These differences can influence how a cancer grows, responds to treatment, and develops resistance.

Depending on the cancer, doctors may use biomarker testing, molecular testing, pathology, imaging, and clinical assessment to better understand the disease.

The central question becomes:

What is driving this cancer—and can that biological pathway be targeted?

First, Find the Molecular Switch

Some cancers are driven by specific genetic abnormalities that activate growth pathways.

A well-known example is chronic myeloid leukemia (CML).

In many patients with CML, the Philadelphia chromosome leads to the formation of the BCR::ABL1 fusion gene. This produces an abnormal tyrosine kinase that continuously sends signals promoting leukemia-cell growth and survival.

Imatinib, a tyrosine kinase inhibitor, targets the BCR::ABL1 protein and inhibits its activity.

This illustrates a fundamental principle of targeted cancer therapy:

Identify the molecular driver → find a compatible target → inhibit the pathway.

The goal is not simply to attack rapidly dividing cells. It is to interfere with a biological mechanism that is helping the cancer grow.

Then, Disrupt the Hormone Signal

Other cancers depend on completely different biological pathways.

In prostate cancer, androgen signaling can play an important role in cancer-cell growth and survival.

Hormones such as testosterone can activate the androgen receptor (AR). Once activated, the receptor can influence gene expression and promote processes that support prostate cancer.

This pathway can be targeted with medicines such as enzalutamide.

Enzalutamide is an androgen receptor inhibitor that interferes with androgen receptor signaling. It can block receptor activation and disrupt downstream processes involved in androgen-driven cancer activity.

The biological principle is different from that of imatinib:

Different cancer driver. Different molecular target. Different treatment strategy.

Why One Treatment Does Not Fit Every Cancer

Two patients may have cancer in the same organ but have tumors with different molecular characteristics.

For example, one tumor may contain a specific genetic alteration that makes it susceptible to a targeted therapy, while another tumor may lack that alteration.

This is why personalized cancer treatment increasingly considers more than just the location of the tumor.

Doctors may evaluate:

• Cancer type and stage
• Genetic and molecular alterations
• Biomarkers
• Pathology findings
• Previous treatments
• Treatment response
• Disease progression
• Overall health
• Potential treatment risks and interactions

These factors can help an oncology team determine which treatment options may be appropriate.

The Role of Molecular Testing in Cancer Care

Molecular testing for cancer can identify specific genetic or biological characteristics of a tumor.

Depending on the cancer type, testing may look for gene mutations, gene fusions, protein expression, or other biomarkers associated with treatment response.

When an actionable molecular alteration is identified, it may provide information that helps oncologists consider a targeted treatment.

However, not every molecular finding has an available treatment, and the presence of a biomarker does not automatically guarantee that a particular therapy will be effective.

That is why molecular results need to be interpreted in the context of the patient’s complete clinical picture.

From Stronger Medicines to Smarter Targets

The evolution of oncology is not simply about developing more powerful medicines.

It is increasingly about understanding why a cancer behaves the way it does.

Targeted therapies can interfere with specific molecular drivers. Hormone-targeted therapies can disrupt signals that cancer cells depend on. Immunotherapies can engage the immune system against cancer.

These approaches demonstrate how different biological mechanisms can require different therapeutic strategies.

The Future of Personalized Cancer Treatment

Cancer research continues to uncover new genetic alterations, signaling pathways, biomarkers, and mechanisms of treatment resistance.

As our understanding of tumor biology improves, precision medicine in oncology may continue to expand.

The future of cancer care is increasingly connected to a deeper understanding of the disease at the molecular level.

The Takeaway

The right cancer treatment depends not only on where the cancer is—but also on what is driving it.

From BCR::ABL1-targeted treatment with imatinib to androgen receptor inhibition with enzalutamide, modern oncology provides examples of how understanding cancer biology can help identify targeted treatment strategies.

Don’t just ask, “What treatment treats this cancer?” Ask, “What is driving this cancer?”

Speak with a qualified oncologist about whether molecular testing, biomarker analysis, or targeted treatment may be relevant to your individual diagnosis.

This article is intended for general educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Treatment decisions should always be made in consultation with a qualified healthcare professional.